aAPC Scaffolds for T Cell Expansion via Merged Stimuli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current artificial antigen presenting cell (aAPC) scaffolds fail to efficiently expand tumor-reactive T cells with sufficient differentiation and functional capacity for effective tumor regression or viral clearance, due to insufficient combinations of stimulatory molecules.
Innovation Solution
Development of aAPC scaffolds with a polymeric backbone attached to pMHC molecules, cytokines such as IL-21, IL-2, IL-15, IL-1, IL-6, IL-10, and IL-7, and co-stimulatory molecules like B7.2 (CD86), CD40, ICOS, and PD-L1, along with optional CD47, to enhance T cell expansion and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If aAPC scaffolds use simple MHC constructs with basic co-stimulatory molecules, then device complexity is reduced, but T cell expansion efficiency and functional capacity are insufficient
Solution Approach 1:
The patent combines multiple stimulatory molecules (pMHC, co-stimulatory molecules like B7.2 and CD40, and cytokines such as IL-21, IL-2, IL-15, IL-1, IL-6, IL-10, and IL-7) into a single integrated aAPC scaffold structure. This merging of multiple functional components into one composite scaffold enables simultaneous delivery of all necessary signals for efficient T cell expansion and functional differentiation, resolving the contradiction between expansion efficiency and device complexity.
Solution Approach 2:
The aAPC scaffold is constructed as a composite structure incorporating diverse molecular components with different functions: antigen presentation (pMHC), co-stimulation (B7.2, CD40), and cytokine signaling (multiple ILs). This composite material approach allows the scaffold to provide multifaceted immunological stimulation, achieving high T cell expansion efficiency and functional capacity while maintaining a unified scaffold architecture.
2Reliability
If aAPC scaffolds incorporate multiple cytokines and co-stimulatory molecules, then T cell functional capacity is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies optimal ratio ranges for scaffold components (e.g., pMHC:co-stimulatory molecule:cytokine ratios) to achieve reliable T cell functional phenotypes. By defining parameter ranges rather than exact values, the invention accommodates manufacturing variations while maintaining functional efficacy. The scaffold design allows flexibility in molecule attachment ratios within specified ranges, reducing manufacturing precision requirements while ensuring consistent T cell outcomes.
3Quantity of substance
If extensive ex vivo culturing is used to expand T cells, then T cell quantity increases, but T cell differentiation and functional capacity are lost
Solution Approach 1:
The aAPC scaffold is pre-loaded with all necessary stimulatory molecules (pMHC, co-stimulatory molecules, and cytokines) before T cell culture initiation. This preliminary preparation ensures that T cells receive optimal immunological signals from the start of culturing, enabling efficient expansion while preserving differentiation and functional capacity. The pre-configured scaffold eliminates the need for sequential addition of multiple factors during culture, maintaining T cell quality throughout the expansion process.
Data Source
AI summary
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.